Author:
Pawinski A.,Wynendaele W.,Van Oosterom A.
Publisher
Springer Berlin Heidelberg
Reference75 articles.
1. Albers P, Bierhoff E, Neu D, Fimmers R, Wernert N, Muller SC (1997) MIB-1 immunochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 79: 1710–1716
2. Allhoff EP, Liedke S, de Riese W, Stief C, Schneider B (1991) Stage I seminoma of the testis. Adjuvant radiotherapy or surveillance. Br J Urol 68: 190–194
3. Baniel J, Roth BJ, Foster RS, Donohue JP (1996) Cost- and risk- benefit considerations in the management of clinical stage I nonseminomatous testicular tumors. Ann Surg Oncol 3: 86–93
4. Bender H, Schomburg A, Albers P, Ruhlmann J, Biersack H-J (1997) Possible role of FDG-PET in the evaluation of uro- logic malignancies. Anticancer Res 17: 1655–1660
5. Bokemeyer C, Kuczyk MA, Serth J, Hartmann JT, Schmoll HJ, Jonas U, Kanz L (1996) Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J Cancer Res Clin Oncol 122: 575–584